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Abstract
Hematopoietic stem cells (HSCs) are probably the best-studied adult tissue-restricted stem cells. Although methods for flow
cytometric detection of phosphoproteins in hematopoeitic progenitors and mature cells are available, analogous protocols
for HSC are lacking. We present a robust method to study intracellular signaling in immunophenotypically-defined murine
HSC/progenitor cell (HPC)-enriched populations. Using this method, we uncover differences in the response dynamics of
several phosphoproteins representative of the Ras/MAP-Kinase(K), PI3K, mTOR and Jak/STAT pathways in HSC/HPCs
stimulated by Scf, Thpo, as well as several other important HSC/HPC agonists.
Citation: Kalaitzidis D, Neel BG (2008) Flow-Cytometric Phosphoprotein Analysis Reveals Agonist and Temporal Differences in Responses of Murine
Hematopoietic Stem/Progenitor Cells. PLoS ONE 3(11): e3776. doi:10.1371/journal.pone.0003776
Editor: Jose Alberola-Ila, Oklahoma Medical Research Foundation, United States of America
Received August 29, 2008; Accepted November 3, 2008; Published November 20, 2008
Copyright:  2008 Kalaitzidis et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: D.K. was supported by an NIH postdoctoral institutional training grant in Hematology (5T32-HL07623-20). This work was supported by RO1 CA114945
and R37 CA49152 awarded to B.G.N. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: dkalaitzidis@partners.org
¤a Current address: Division of Hematology, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, United
States of America
¤b Current address: Division of Stem Cell and Developmental Biology, Ontario Cancer Institute, Ontario, Canada
Introduction
HSCs self-renew and give rise to all hematopoietic cells. Adult
murine HSCs can be prospectively enriched by their low expression
of multiple lineage markers (LIN
2) including CD127, and high
expression of c-Kit (hereafter, Kit) and Sca-1, as well as several other
markers [1]. HSC with long-term (LT) repopulating activity (CD34
2)
can be further purified from short-term (ST)-HSC and multipotent
progenitors (MPP) (CD34
+) usingCD34 antibodies.MPPsgive rise to
lineage-restricted progenitors with minimal self-renewal and more
restricted differentiation capacities, including common lymphoid
progenitors (CLPs; LIN
2c-Kit
loSca-1
loCD34
+CD127
+), lymphoid-
primed MPPs (LMPPs; LIN
2c-Kit
+Sca-1
+CD34
+Flt3
+CD127
+/2),
and common myeloid progenitors (CMPs) [1]. CMPs (LIN
2c-
Kit
+Sca-1
2CD34
+FccRII/III
loCD127
2) yield granulocyte/mono-
cyte progenitors (GMPs: LIN
2c-Kit
+Sca-1
2CD34
+FccRII/
III
+CD127
2) and megakaryocyte/erythroid progenitors (MEP-
s:LIN
2c-Kit
+Sca-1
2CD34
2FccRII/III
2CD127
2), which ultimately
give rise to all red and white blood cells, including platelets. The
LIN
2c-Kit
+Sca-1
+ (LSK) fraction of the bone marrow (BM) is
enriched for HSCs and MPPs, whereas the LIN
2c-Kit
+Sca-1
2 (LK)
fraction contains CMPs, GMPs and MEPs [1].
Much progress has been made in determining the physiological
function of HSCs/HPCs. Less is known about their biochemical
responses to various agonists, largely because traditional ap-
proaches (e.g., immunoblotting) are not applicable to such rare
cells. Recently, murine HSC purified by Fluorescence-Activated
Cell Sorting (FACS) were stimulated ex vivo, and changes in their
phosphoprotein levels were visualized by immunofluoresence [2].
Although this approach provides some insights into HSC signaling
and also permits the analysis of protein subcellular localization, it
only allows analysis of one cellular population at a time and is
subject to the limitations of immunofluorescence (e.g., difficulties
in quantification, photobleaching, etc.). BM cells also have been
stimulated ex vivo, then fixed, permeabilized, immunostained for
surface and intracellular markers, and analyzed by FACS [3].
However, this method only permits analysis of the highly
heterogeneous LIN
2Kit
+ population. There is one report of
intracellular staining of LIN
2 cells that were first surface-stained
for Sca-1 and Kit, and then fixed and saponin-permeabilized with
a commercial kit [4]. However, this permeabilization agent may
not be optimal for HSC/HPC signaling studies (see below).
We have optimized conditions to analyze signal transduction
pathways in phenotypically-defined HSC/HPC subsets. We
focused on two well-characterized agonists, stem cell factor (Scf)
and thrombopoietin (Thpo), as well as several other important
HSC/HPC growth factors and cytokines, and demonstrate robust
responses in several well-studied signaling pathways. Using our
approach we observed signaling cross-talk between the MEK and
mammalian target of rapamycin (mTOR) pathways, converging
on ribosomal protein S6 phosphorylation in HSC/HPC.
Results
Fixation conditions for retaining surface antigenicity of
sorted Lin
2 cells
We sought a robust protocol for multi-parametric, quantitative
analysis of intracellular signaling in phenotypically-defined murine
stem/progenitor cell populations [5–7]. Previous studies showed
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FACS after paraformaldehyde (PFA) fixation and alcohol-based
permeabilizaton [5], and established that alcohol- (or ketone-)
based permeabilization is superior to detergents for preserving
intracellular phosphoproteins [6]. A major barrier to applying
these methods to HSCs/HPCs arises from the requirement that
multiple lineage markers be used to enrich for the LIN
2 HSC/
HPC compartment (Materials and Methods). Some important
extracellular antigens lose antigenicity after fixation/permeabiliza-
tion [5], and contamination of the LIN
2 compartment with LIN
+
cells rendered artifactually ‘‘LIN
2’’ by fixation/permeabilization
could seriously confound analysis. We decided to enrich for HSC/
HPC by first removing LIN
+ and dead cells (propidium iodide
[PI]
+) by FACS (Figure 1A and B). We avoided positive selection
with HSC/HPC-specific antigens to limit potential antibody-
triggered signaling events [8]. LIN
2 cells represent a minority of
murine BM (,15%), and we obtained this population at
reasonably high purity with an average yield of 5.75610
5 (6)
2.38610
5 cells/mouse (mean6standard deviation [SD]; n=13
independent experiments; Figure 1B). A minimum of 1610
5
LIN
2PI
2 cells, comprising ,100 LSK and .200 LK cells after
fixation/permeabilization, is sufficient for analysis of signaling
events following brief ex vivo culture and agonist stimulation
(Figure 1A and data not shown).
We next sought conditions that preserve surface antigens on
HSC/HPC. Consistent with previous reports [3,5], Kit staining
was maintained after PFA fixation and permeabilization with
multiple agents (Figure 1C and S1). However, Sca-1 antigenicity
was destroyed after PFA fixation and methanol permeabilization
[3], and significantly reduced following PFA fixation and
permabilization with either ethanol, methanol, isopropranol,
Triton (0.50%), or two concentrations of saponin. Saponin
permeabilization also increased non-specific binding (Figure S1).
There was considerable retention of Sca-1 antigenicity on
LIN
2Kit
+ cells following acetone or 0.10% Triton treatment
(Figure 1C and S1), although the median fluorescent intensity
(MFI) of these cells relative to untreated or PFA-fixed cells was
reduced. After adjusting the gating to account for the reduced
MFI, a distinct population of LSK cells could still be identified.
Acetone was superior to Triton in preserving Sca-1 antigenicity (as
indicated by the significantly higher MFI) in the LIN
2Kit
+
population (Figure S1), and was reported previously to provide
superior preservation of intracellular phosphoprotein epitopes
(compared to detergents) [6]; thus, we used acetone in all
subsequent experiments.
Sca-1 staining on LIN
2Kit
+ cells was specific, as BM from
BALB/c mice, which express low/no levels of Sca-1 [9], showed a
substantially reduced LSK population compared to the C57BL/6
BM used above and in all other experiments (Figure 1C). The
percentage of cells retaining CD34 antigenicity (and the CD34
MFI) also was comparable in untreated and PFA-fixed/acetone-
permeabilized cells (Figure 1D), allowing discrimination of LT-
HSC (CD34
2) from ST-HSC/MPP (CD34
+) [10] and GMP/
CMP (CD34
+) from MEP (CD34
2)-enriched populations within
the LK compartment [11]. We also obtained satisfactory staining
for fms-like tyrosine kinase 3/fetal liver kinase 2 (Flt3/Flk2) and
CD48, either of which can further be used to discriminate between
HPCs, MPPs and LT/ST-HSC [12–14] (Figure S2, Materials and
Methods S1). However, we could not obtain conditions for
FccRII/III (PE-Cy7-conjugate of clone 93) staining, which would
allow discrimination of GMPs from CMPs, nor for CD150/Slam
(with either PE or PE-Cy7 conjugates of clone TC15-12F12.2),
which, like CD34 or Flk2/Flt3, also can discriminate LT-HSC
from MPPs (data not shown).
Detection of agonist-evoked changes in intracellular
phosphoproteins in HSC/HPC
We stimulated LSK, LK and LIN
2Kit
2Sca-1
2 (LDN) cells
with two agonists that have well-established roles in HSC/HPC
physiology, Scf or Thpo, and asked if intracellular phosphopro-
teins could be detected. The receptor for Scf, Kit, is expressed on
all HSC/HPC (see above), and the Thpo receptor, c-Mpl, is
expressed (at the mRNA level) in HSC/CMP/MEP but not GMP
[11]. Sorted LIN
2/PI
2 cells were cultured briefly in low serum-
containing media for ,1 hour (Figure 1A, Materials and
Methods), stimulated for 5 min with Scf (100 ng/ml) or Thpo
(50 ng/ml), fixed and permeabilized as above, stained simulta-
neously for surface and intracellular antigens, and analyzed by
flow cytometry (Figure 2A). As representatives of major cytokine
and growth factor signaling pathways, we probed for phosphor-
ylated(p)-ERK1/2 (Thr202/Tyr204), p-AKT (Ser473), p-ribo-
somal protein S6 (Ser235/236), p-STAT5 (Tyr694), and p-
STAT3 (Tyr705).
Following Scf treatment, robust pERK and pS6 responses were
observed in LSK and LK, but not LDN cells (Figure 2A;
quantified in Figure S3). The pERK response was specific, as it
was eliminated by pre-treating cells with the MEK inhibitor
UO126 (Figure 2A). S6 can be phosphorylated on Ser235/236 as
a consequence of mTOR or ERK activation [15]. Scf-evoked
phosphorylation of these residues at 5 min in either LSK or LK
cells was primarily UO126-, not rapamycin-sensitive, and
therefore MEK, rather than mTOR-dependent (Figure 2A). We
also observed a small, PI3K-dependent response, in pAKT
(Figure 2A). We failed to detect significant Scf-evoked increases
in STAT3 or STAT5 phosphorylation in any of the cell
populations examined (Figure 2A). Although this could indicate
a lower sensitivity for detecting pSTAT than other p-epitopes,
phosphorylation of both STAT proteins was detected in response
to Thpo, as well as several other agonists (see below).
Thpo also induced a strong increase in pERK and pS6 in LSK
cells. Unlike Scf, which affected LSK and LK populations equally,
Thpo-evoked responses were lower in LK cells (Figure 2A). Thpo
also evoked a small, but specific, increase in pAKT (Figure 2A).
Unlike Scf, Thpo induced significant increases in pSTAT5 and
pSTAT3 in LSK cells and in pSTAT5 alone in LK cells
(Figure 2A). Consistent with our findings, Thpo-evoked increases
in pAKT, pSTAT5 and pSTAT3 were observed previously in
LSK CD34
2 cells using immunofluorescence-based assays [2,16].
Treatment with either Scf or Thpo and/or various kinase
inhibitors had no effect on surface marker antigenicity in either
cell population (Figure S4).
We also assessed phosphoprotein responses to other agonists
commonly used ex vivo in HSC/HPC assays and culture
conditions. Flt3 ligand (Flt3L) evoked strong increases in pERK
and pS6 in most LSK cells and a minority of LK cells, and a
smaller response in pAKT levels in LSK cells (Figure 2B;
quantified in Figure S5). Like Scf, also a receptor tyrosine kinase
agonist, Flt3L failed to evoke detectable changes in STAT
phosphorylation (Figure 2B). Interleukin-3 (IL-3) elicited stronger
responses in LK cells than in LSK cells, and increased pERK, pS6,
and to a lesser extent pSTAT5 (Figure 2B and S5). Granulocyte/
macrophage colony-stimulating factor (Gm-csf) evoked small
increases in pERK, pS6 and pSTAT5, predominantly in LK
cells, consistent with Gm-csf receptor levels being detected in
GMP [17] (Figure 2B and S5). In both LSK and LK cells, IL-6
only evoked STAT3 phosphorylation with no changes in any of
the other phosphoproteins analyzed (Figure 2B and S5).
Using CD34 staining, we also analyzed signaling responses in
more refined LSK/LK subsets (Figure 3, S6, and S7). Scf evoked
Signal Transduction in HSC/HPC
PLoS ONE | www.plosone.org 2 November 2008 | Volume 3 | Issue 11 | e3776Figure 1. Surface marker expression in paraformaldedyde (PFA)-fixed (Fix), acetone-permeabilized (Perm) LIN
2/PI
2 cells. A,
Schematic showing approach for enriching HSC/HPC populations and analyzing intracellular (IC) and extracellular (surface) antigens. B, Murine BM
cells were stained with LIN markers and PI. ‘‘Primary Sort’’ indicates typical gates for LIN
2/PI
2 cells after debris and cell clumps were gated using
forward scatter/side scatter (FSC/SSC). ‘‘Re-analysis’’ represents cells analyzed for LIN/PI staining immediately after sorting. Numbers indicate
percentage (6) standard deviation (SD) (n=5) of LIN/PI-stained BM cells before and after sorting. C, Cells were sorted as in (B), incubated in vitro at
37uC for ,1 hour in 2% FBS/IMDM, and either left untreated, fixed with 1.5% PFA without permeabilization, or fixed with PFA and subsequently
permeabilized with ice-cold ,100% acetone. Cells were then stained with Kit (APC-conjugate) and Sca-1 (PE-conjugate) antibodies and analyzed with
a flow cytometer. Shown are pseudocolor dot plots and gating schemes, along with staining of BM from BALB/c mice, which express low levels of
Sca-1 [9]. The percentage of the parental gate 6SD from 4 independent experiments is indicated. LK, LIN
2Kit
+Sca-1
2, LSK, LIN
2Kit
+,Sca-1
+, LDN,
LIN
2Kit
2Sca-1
2. A minimum of 2,500 events was collected (not counting cells with high SSC and low FSC, gated as in panel (B), and hereafter, termed
Signal Transduction in HSC/HPC
PLoS ONE | www.plosone.org 3 November 2008 | Volume 3 | Issue 11 | e3776Figure 2. Differential responses of defined LIN
2 populations to various agonists. A, LIN
2/PI
2 BM cells were sorted and incubated in vitro
in 2% FBS/IMDM for ,1 hour. Where indicated, cells were pre-incubated with inhibitors for 30 minutes–1 hour prior to stimulation for 5 minutes
with the indicated agonists (100 ng/ml Scf or 50 ng/ml Thpo). Cells were fixed immediately, permeabilized, washed several times and stained for
extracellular antigens (as in Figure 1) and the indicated phosphoproteins. Data are presented as the log of fluorescence intensity on the x-axis and the
% maximal value on the y-axis, and are representative of at least 2–3 independent experiments (See Figure S3 for quantification of the changes in MFI
in response to the various treatments). Minima of 3,700 and 1,300 FSC/SSC-gated events were collected for the Scf and Thpo experiments,
respectively. UO: 10 mM UO126 for 30 minutes, LY: 20 mM Ly294002 for 30 minutes, R: 100 nM rapamycin for 30 minutes, JI,:1 mM Jak inhibitor I for
1 hour. (See text and Materials and Methods for the specific phosphorylation sites interrogated on each phosphoprotein). B, Cells were treated with
the indicated agonists (50 ng/ml Flt3L, 10 ng/ml IL-3, 20 ng/ml Gm-csf, 20 ng/ml IL-6) for 5 minutes and processed as in (A). Data are displayed as in
(A) and are representative of at least 2 independent experiments. A minimum of 2,700 FSC/SSC-gated events was collected (See Figure S5 for
quantification of the responses to the various treatments).
doi:10.1371/journal.pone.0003776.g002
‘‘FSC/SSC-gated events’’). D, LIN
2/PI
2 cells were left untreated or fixed, permeabilized, and stained for Sca-1 and Kit (as above), as well as CD34
(Pacific Blue-conjugate). Shown are pseudocolor dot plots, contour plots, and the percentage of the parental gates (from one of several experiments).
A minimum of 1,500 FSC/SSC-gated events was collected. CD34 gates were set according to fluorescence minus one controls (data not shown). LT,
long-term HSC, MPP, multipotent progenitors, GMP, granulocyte/monocyte progenitors, CMP, common-myeloid progenitors, MEP, megakaryocyte/
erythroid progenitors.
doi:10.1371/journal.pone.0003776.g001
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PLoS ONE | www.plosone.org 4 November 2008 | Volume 3 | Issue 11 | e3776Figure 3. Detection of phosphoproteins in CD34-defined LSK/LK subsets. A, Cells were treated as in Figure 2A and gated for CD34
expression and pERK (Thr202/Tyr204) levels. Contour plots and percentage of parental gates are shown from a representative experiment performed
at least twice. Minima of 6,000, 4,700, and 2,700 FSC/SSC-gated events were collected for the Scf, Thpo, and other agonist experiments, respectively.
Using CD34-gated HSC/HPC subsets permit analysis of signaling events in more discretely defined HSC/HPC populations. B, Cells were treated with
Thpo for 5 minutes, processed as described above, and stained simultaneously for surface markers, pS6 (Ser235/236), and pSTAT5 (Tyr694) in the
indicated LSK and LK subsets (gated as in Figure 1D). Data are representative of 2 independent experiments, with a minimum of 7,400 FSC/SSC-gated
events collected. Note the ability to simultaneously detect multiple phospho-epitopes in defined HSC/HPC subsets.
doi:10.1371/journal.pone.0003776.g003
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PLoS ONE | www.plosone.org 5 November 2008 | Volume 3 | Issue 11 | e3776nearly uniform ERK phosphorylation in LSK and LK subsets. In
contrast, Thpo responses were more heterogeneous. Most LSK
cells increased pERK levels in response to Thpo, yet a substantial
minority of CD34
+/CD34
2 LSK cells did not respond (Figure 3A).
The response to Thpo in LK cells was also heterogeneous, with
only minor fractions of CD34-positive and -negative cells showing
activation (Figure 3A). These findings are consistent with
expression of c-Mpl on CD34
+ CMPs and CD34
2 MEPs [11].
Flt3L also evoked a heterogeneous response in LSK and LK cells.
In both, LSK and LK cells, elevated Flt3L-evoked pERK levels
were mostly detected in CD34
+ cells, although some of these cells
showed no increase in pERK (Figure 3A and S2). IL-3-evoked
phosphorylation of ERK was equivalent in CD34
+ and CD34
2
LSK cells, but was stronger in CD34
+ LK cells (as opposed to
CD34
2 cells). In contrast, Gm-csf responses were more apparent
in LK cells, with a subset of CD34
+ LK cells responding
(Figure 3A) [17]. Other phosphoprotein signaling responses
measured in LSK/LK CD34 subsets are presented in Figure S6
and S7. Finally, by using antibodies to pS6 and pSTAT5, we
found that several phosphoproteins can be quantified simulta-
neously in single cells from all of the LSK and LK CD34 subsets
tested (Figure 3B).
Kinetics of signaling events in HSC/HPC
Our initial analyses were performed to assess the selectivity and
sensitivity of our protocol and focused on an early time point
(5 minutes), which would presumably reveal strong responses and
be less influenced by pathway cross-talk. Subsequently, we
characterized later responses in several phosphoproteins. Scf-
evoked ERK phosphorylation (Thr202/Tyr204) was elevated
5 minutes post-stimulation, rapidly declined by 15 minutes and
remained at baseline levels for at least 30 minutes post-stimulation
in LSK and LK cells (Figure 4A and data not shown). We
observed similar kinetics of response in pERK in response to Thpo
(data not shown). Scf- and Thpo- evoked S6 phosphorylation
typically peaked by 5 minutes post-stimulation in both LSK and
LK cells, declined gradually starting at 15 minutes, and returned
to near-baseline levels at 30 minutes for Thpo and 1 hour for Scf
(Figure 4B). Scf-evoked pS6 responses were significantly higher
than Thpo-evoked responses in LSK and LK cells throughout the
time course (Figure 4B). The combination of Scf and Thpo did not
lead to an enhanced pS6 response relative to Scf treatment at most
time points in either LSK or LK cells (Figure 4B). However, S6
phosphorylation was sustained significantly in LSK, but not LK
cells, when both agonists were used compared to either agonist
alone (Figure 4B; Fold change in MFI at 60 minutes with
Scf+Thpo: 7.0762.14; Scf alone: 1.6260.13 p=0.04; Thpo
alone: 1.4760.15, p=0.04).
As noted above (Figure 2 and S3), pSTAT5 levels were higher
in Thpo-stimulated LSK cells, compared to Scf-stimulated cells.
These levels appeared to peak at 15 minutes post-Thpo stimula-
tion, and remained elevated slightly even at 60 minutes in LSK
cells (Figure 4B). Scf did not affect STAT5 phosphorylation
appreciably over this time course either alone or in combination
with Thpo treatment (Figure 4B).
Differential control of S6 phosphorylation at Ser235/236
in HSC/HPC
Scf-evoked phosphorylation of ribosomal protein S6 at Ser235/
236 at 5 minutes was completely sensitive to MEK inhibition and
insensitive to mTOR inhibition (Figure 2A and S3). However, S6
phosphorylation remained elevated at 15 minutes post-Scf addi-
tion, whereas pERK levels declined rapidly after 5 minutes
(Figure 4A and B). At 15 minutes post-Scf addition, pS6 levels
were both MEK- and mTOR-dependent in LSK and LK cells, as
the fold change in MFI for pS6 was reduced by either UO126 or
rapamycin pre-treatment. These data are similar to previously
reported results on mouse and human cell lines [15,18], and
provide proof of principle for the utility in pathway analysis of our
phosphoflow protocol in HSC/HPC-enriched populations.
Discussion
We have developed a protocol that utilizes the multi-parametric
and quantitative attributes of FACS to examine multiple phosphor-
ylation events at the single cell level in highly purified HSC/HPC
populations. Previous studies have only been able to analyze
signaling events in bulk hematopoietic progenitors by flow
cytometry [3] or one cellular parameter at a time by immunoflu-
orescence-based techniques [2]. Although still limited by low target
cell numbers and loss of a significant proportion of the starting
material post fixation/permeabilization and washing steps, our
protocol permits the simultaneous analysis of multiple cellular
(HSC, MPP, GMP/CMP, MEP), and intracellular parameters in
HSC/HPC, akin to studies of more mature hematopoietic cells [6].
Intracellular signaling networks in HSC/HPC have remained
largely unexplored territory, mostly due to the rarity of these cell
populations. Here we have analyzed signal transduction responses
to several HSC/HPC agonists, including Scf and Thpo, both of
which are important in vivo for HSC function and can promote
survival and enhance the proliferation of HSC/HPC ex vivo [2,19–
23]. Although Scf elicited rapid responses in some intracellular
pathways that we interrogated (Ras/MAPK, PI3K/AKT) in all of
the HSC/HPC cellular subsets we analyzed, Thpo stimulation
profiles were stronger in HSC/MPP (compared to GMP/CMP or
MEP) and consisted of the activation of a broader array of
intracellular pathways (Ras/MAPK, PI3K/AKT, JAK/STAT).
Other agonists, such as Flt3L, appeared to elicit stronger responses
in LSK compared to LK cells, whereas Gm-csf elicited stronger
responses in LK cells. These differences in response could reflect a
heterogeneous expression of receptors in LSK and LK cells, as
well as differences in the intrinsic sensitivity to these agonists
between populations. We detected a significant synergistic effect of
Scf and Thpo relative to either treatment alone on pS6 levels in
LSK, resulting in a sustained pS6 response (Figure 4B). It is
tempting to speculate that the reason for biological synergy (in
terms of colony formation or proliferation/survival of HSC/HPC)
previously observed between Scf and Thpo [2,19–21] reflects
sustained Ras/MAPK and mTOR signaling, although further
genetic- or pharmacology-based biological assays are required to
explore this point. Recent studies have demonstrated that both
Thpo and Kit are required to maintain the steady-state pool of
adult quiescent HSC [22,24]. While STAT5 plays a significant
role in HSC function [16,25,26], the role of members of the Ras/
MAPK or mTOR pathway in HSC biology remains largely
unexplored. Our data suggest that these pathways likely play a role
downstream of agonist stimulation in HSC/HPC.
We also simultaneously assessed responses in pS6/pSTAT5 in
CD34-LSK and LK subsets (Figure 3B). In all populations
analyzed, approximately half of the cells respond to Thpo
stimulation by elevating both pS6 and pSTAT5, but the rest only
elevate pS6 (Figure 3B). This could reflect the relative hypersen-
sitivity of the pathways downstream of Thpo leading to S6
phosphorylation over signaling to STAT5, lower sensitivity of our
conditions for detecting pSTAT5, or intrinsic heterogeneity in the
cell types present in these compartments. Regardless, the
physiological relevance of this heterogeneity in signaling responses
merits further investigation.
Signal Transduction in HSC/HPC
PLoS ONE | www.plosone.org 6 November 2008 | Volume 3 | Issue 11 | e3776Figure 4. Kinetic and pathway analysis in HSC/HPC subsets. A, Cells were treated with Scf for the indicated time in minutes (min) and
processed as above. Levels of pERK were monitored and normalized to untreated controls in the indicated populations (Fold D MFI). Data represent
the mean of two independent experiments 6SD. B, Cells were treated for various times (min) with the indicated agonists and levels of pS6 (Ser235/
236) and pSTAT5 (Tyr694) in the HSC/HPC subsets were quantified. Data are normalized to untreated controls in each indicated population (Fold D
MFI). Data points represent the average from 4 independent experiments (except for the Scf+Thpo 30 minute time point, which is from 3
experiments) shown 6SEM. (*P,.05). Red squares, Scf, blue triangles, Thpo, green circles, Scf+Thpo. C, Cells were treated with Scf and the indicated
inhibitors (Drug) over the depicted amount of time (min) and pS6 (Ser235/236) levels were monitored in LSK and LK cells. Levels of pS6 were
quantified as above, and the means of at least 4 independent experiments 6SEM are shown. (*P,.05, **P,.01). UO, UO126, R, Rapamycin.
doi:10.1371/journal.pone.0003776.g004
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PLoS ONE | www.plosone.org 7 November 2008 | Volume 3 | Issue 11 | e3776Our approach can be used along with selective inhibitors to
examine pathway-dependencies. For example, our analysis of Scf-
evoked S6 phosphorylation in primary HSC/HPC is largely in
agreement with that of Roux et al. [15], who demonstrated that
serum-evoked S6 phosphorylation at Ser235/236 in human cell
lines (HEK 293) is dependent on an early MEK-dependent
pathway (through RSK) and a later MEK- and mTOR-dependent
pathway. Our data are also consistent with the Mek-inhibitor
sensitivity of Ser235/236 phospohorylation in mouse embryonic
fibroblasts doubly deficient for the mTOR downstream kinases
S6K1/2 [18]. Our results suggest a model in which Scf stimulation
leads to ERK activation that likely leads to RSK1/2 activation
and S6 phosphorylation at Ser235/236 at 5 minutes post
stimulation. At 15 minutes, S6 phosphorylation, is still partially
UO126- and rapamycin- sensitive, although levels of pERK have
returned to baseline at this time point. ERK activation also can
lead to TSC2 phosphorylation and inactivation [27]. Our data
suggests the intriguing possibility that ERK mediated TSC2
inactivation is required along with mTOR-dependent phosphor-
ylation of S6 to sustain high levels of pS6 in HSC/HPC. Direct
testing of this model will be possible with the availability of
appropriate phosphospecific antibodies.
Finally, our protocol should be amenable to the study of signal
transduction abnormalities in leukemia stem cells (LSC), as these
cells often share phenotypic similarities with normal HSC/HPC
[17,28]. The effects of drugs that may affect deregulated signal
transduction pathways in leukemia can be readily tested in cell
populations expressing surface epitopes examined in this study.
Materials and Methods
Antibodies, reagents
Lineage-specific antigens were stained with the following
antibodies, all conjugated to PE-Cy5: CD3e (145-2C11, BioLe-
gend, San Diego, CA), CD4 (RM4-5, eBioscience, San Diego,
CA), CD8a (53-6.7, BioLegend), CD19 (6D5, BioLegend),
CD45R (RA3-6B2, eBioscience), CD127 (A7R34, eBioscience),
Ly-6G (RB6-8C5, eBioscience), and Ter119 (TER119, BioLe-
gend). Antibodies against c-Kit (APC-conjugated, 2B8,
eBioscience), Sca-1 (PE-conjugated, D7, eBioscience) and CD34
(Pacific Blue conjugated, RAM34, eBioscience) were also used.
The following monoclonal antibodies were used to detect
intracellular phosphoproteins: pERK [Thr202/Tyr204] (Alexa
Fluor [Ax] 488-conjugated, E10, Cell Signaling, Danvers, MA),
pAKT [Ser 473] (Ax488-conjugated, 193H12, Cell Signaling),
pS6 [Ser235/236] (Ax488-conjugated, D57.2.2E, Cell Signaling),
pSTAT5 [Tyr694] (PE-Cy7- conjugated, 47, Becton Dickinson
[BD] Biosciences, San Jose, CA), and pSTAT3 [Tyr705] (Ax488-
conjugated, D3A7, Cell Signaling). UO126, Ly294002, and Jak
Inhibitor I were purchased from Calbiochem (La Jolla, CA).
Rapamycin was purchased from Cell Signaling. Recombinant
murine forms of Scf, Thpo, Flt3L, IL-3, Gm-csf and IL-6 were
purchased from Peprotech (Rocky Hill, NJ) and dissolved in
0.10% BSA/PBS. PFA was purchased from Electron Microscopy
Sciences (Hatfield, PA).
Cell preparation and FACS
BM was harvested from both limbs of 8–12-week-old C57BL/6
or BALB/c mice (Charles River Laboratories, Wilmington, MA)
euthanized by CO2 asphyxiation, followed by cervical dislocation,
flushed into cold 2% FBS/IMDM and passed through a 40 mm
cell strainer (BD Falcon). Cells were collected by centrifugation,
and red blood cells were lysed in 0.16 M NH4Cl on ice. Cells were
then washed, centrifuged, resuspended in 400 ml of cold 2% FBS/
IMDM, and stained with saturating levels of antibodies against the
above lineage markers for ,15 minutes on ice. After washing, cells
were passed through a 40 mm cell strainer into 5-ml polypropylene
round-bottom tubes (BD), and stained with 1 mg/ml PI (Invitro-
gen, Carlsbad, CA). LIN
2/PI
2 cells were purified using a
FACSAria (BD). All mouse studies were approved by our
Institutional Animal Care and Use Committee.
Cell treatment and staining
Cells were fixed, permeabilized, and stained essentially as
described previously, but using PFA fixation, followed by
permeabilization with acetone [5,6]. Sorted cells were placed into
Eppendorf tubes, pelleted at 6,000 rpm on a benchtop centrifuge,
and resuspended in 2% FBS/IMDM. A minimum of 1610
5 cells
was aliquoted into Eppendorf tubes. After fixation, permeabilizea-
tion, staining and several washes, there is considerable cell loss.
Staining the above minimum of cells ensures that adequate events
are acquired during re-analysis for statistically meaningful results
(e.g., ,100 LSK cells, .200–300 LK cells). Where indicated, cells
were treated with various drugs and/or agonists (5 minutes with
100 ng/ml Scf, 50 ng/ml Thpo, 50 ng/ml Flt3L, 10 ng/ml IL-3,
20 ng/ml Gm-csf, or 20 ng/ml IL-6) at 37uC in a humidified
incubator, and fixed immediately after the desired treatment times
in 1.5% paraformaldehyde (final concentration) for 10 minutes at
room temperature. Untreated (minus) cells were received 0.10%
BSA/PBS and vehicle (DMSO). Fixed cells were collected by
centrifugation at 6,000 rpm for 3 minutes, and resuspended in
,100% ice-cold acetone (Fisher Scientific, Pittsburgh, PA), added
drop-wise with simultaneous gentle vortexing. After ,10 minutes
on ice, cells were collected as above, washed twice with 1 ml of
PBS/0.50%BSA/0.02%NaN3, and aliquoted into the number of
Eppendorf tubes desired for intracellular stainings (100 ml each).
Cells were stained for 20 minutes at room temperature in the dark
with the indicated antibodies at the following final concentrations:
anti-Sca-1 (2 ng/ml), anti-Kit (4 ng/ml), anti-CD34 (2 ng/ml for
fix/perm cells; 5 ng/ml for untreated cells), anti-pERK (2 ng/ml),
anti-pAKT (0.5 ng/ml), anti-pS6 (0.1 ng/ml), anti-pSTAT5 (1:5 or
1:10; no concentration specified by supplier), and anti-pSTAT3
(4 ng/ml). Cells were then washed with 10 volumes of PBS/
0.50%BSA/0.02%NaN3, placed in 5-ml polystyrene round-
bottom tubes (BD) in 300 mL of PBS/0.50%BSA/0.02%NaN3,
and analyzed on an LSRII (BD). Compensation was calculated by
using whole BM cells stained with directly-conjugated anti-
CD45R antibodies (FITC, PE, PE-Cy5, APC, PE-Cy7, Pacific
Blue). Data were analyzed using FlowJo software (TreeStar,
Ashland, OR).
Statistical analysis
The statistical significance of differences between population
means was assessed by 2-tailed unpaired Student t test.
Supporting Information
Materials and Methods S1
Found at: doi:10.1371/journal.pone.0003776.s001 (0.03 MB
DOC)
Figure S1 Effect of fixation/permeabilization conditions on Sca-
1 staining. A, Cells were either left untreated or fixed with PFA
without permeabilization, and subsequently stained for Kit and
Sca-1. B, Cells were treated as in (A), and permeabilized with the
indicated agents post-fixation. A mimimum of 1,400 FSC/SSC-
gated events was collected for each treatment. Saponin was
included in the permeabilization and wash/staining buffer when
used. C, The median fluorescence intensity (MFI) is shown for
Signal Transduction in HSC/HPC
PLoS ONE | www.plosone.org 8 November 2008 | Volume 3 | Issue 11 | e3776Sca-1 staining with a PE-conjugated antibody post-fixation with
PFA and permeabilization with the indicated agents. MFIs are
from the LIN-Kit+Sca-1+ gate. The MFI from PFA-fixed/
acetone-permeabilized cells was reduced compared to PFA-fixed
cells that were not permeabilized in the LIN-Kit+Sca-1+ gate.
Data are from a representative experiment.
Found at: doi:10.1371/journal.pone.0003776.s002 (0.99 MB TIF)
Figure S2 Flt3 and CD48 staining. A, Cells were left untreated
or fixed and permeabilized (fix/perm) with PFA and acetone,
respectively, and stained with FITC-conjugated Sca-1, APC-
conjugated c-Kit and PE-conjugated Flt3 antibodies. The
percentage of cells staining positive in each population subset for
Flt3 is indicated from one representative experiment. Notice the
fluorescence intensity of Flt3 post-fix/perm is reduced although
there is retention in percent positive cells relative to untreated
samples. B, Cells were treated as in (A) and stained with Pacific
Blue-conjugated CD48 and APC-conjugated c-Kit antibodies.
The percentage of cells staining positive in each population subset
for CD48 is indicated from one representative experiment
Found at: doi:10.1371/journal.pone.0003776.s003 (7.31 MB TIF)
Figure S3 Quantification of signaling changes in response to Scf
or Thpo in HSC/HPCs. The fold change (D) in MFI was
calculated by dividing the MFI of stimulated/drug-treated cells
with that of unstimulated cells. For each agonist, values are
normalized to unstimulated cells in individual cell subsets (LSK
values are relative to unstimulated LSK; LK values are relative to
unstimulated LK). Bar graphs represent the means from 2
independent experiments. Error bars indicate the SD. Abbrevia-
tions are as in Figure 2.
Found at: doi:10.1371/journal.pone.0003776.s004 (5.86 MB TIF)
Figure S4 No change in extracellular surface marker levels in
agonist/drug-treated HSC/HPC. Cells were treated as in Figure 2,
and the percentages of LSK, LK, and LDN cells (as in Figure 1)
were assessed. Data are representative of 2–3 independent
experiments, and percentage of the parental gate from 1
experiment is shown.
Found at: doi:10.1371/journal.pone.0003776.s005 (7.63 MB TIF)
Figure S5 Quantification of changes in MFI of phosphoprotein
epitopes in response to other agonists. The fold change (D) in MFI
was calculated by dividing the MFI of stimulated/drug-treated
cells with that of unstimulated cells as in Figure S3. Bar graphs
represent the means from 2 independent experiments. Error bars
indicate the SD. Abbreviations are as in Figure 2.
Found at: doi:10.1371/journal.pone.0003776.s006 (5.35 MB TIF)
Figure S6 Responses of CD34/phosphoprotein subsets to Scf or
Thpo stimulation. Cells were treated as in Figure 2, and gated for
the indicated cell surface and intracellular markers with or without
stimulation by the indicated agonists. Results are representative of
2–3 independent experiments, with the percentage of the parental
gates from 1 experiment indicated
Found at: doi:10.1371/journal.pone.0003776.s007 (6.79 MB TIF)
Figure S7 Responses of CD34/phosphoprotein subsets to other
agonists. Cells were treated as in Figure 2, and gated for the
indicated cell surface and intracellular markers with or without
stimulation by the indicated agonists. Results are representative of
2 independent experiments, with the percentage of the parental
gates from 1 experiment indicated. NC, No Change.
Found at: doi:10.1371/journal.pone.0003776.s008 (7.09 MB TIF)
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